Signant Health announced the acquisition of Ametris in a move designed to combine electronic clinical outcome assessment (eCOA) solutions with wearable-derived digital outcome measures for clinical trials.
The acquisition creates a unified platform that integrates patient-reported outcomes with continuous sensor data, enabling sponsors to build stronger and more comprehensive efficacy cases for regulatory submissions. By combining both modalities into a single platform, the companies aim to simplify multimodal clinical studies, reduce operational complexity, and accelerate insights for sponsors.
Clinical trials increasingly require multiple evidence streams to demonstrate meaningful treatment benefit. Traditionally, sponsors have had to manage multiple vendors and integrate separate datasets across patient-reported outcomes and sensor-based measures. The combined company said the acquisition addresses these challenges through a single-provider approach backed by scientific and regulatory expertise across both domains.
The combined platform is expected to support more seamless workflows through unified data flows, coordinated deployment tools, and integrated analytics capabilities. Future roadmap initiatives include artificial intelligence and machine learning technologies designed to identify patterns across patient-reported and sensor-derived data, enabling the development of novel digital and composite outcome measures as well as real-time trial insights.
Founded in 2004 as ActiGraph before rebranding to Ametris, the company specializes in wearable technologies, regulatory-aligned analytics, and scientific support services designed to transform real-world patient data into validated clinical evidence. Signant Health has spent more than 25 years providing evidence generation solutions for pharmaceutical sponsors and CROs across traditional, hybrid, and virtual clinical trial environments.
KEY QUOTES:
“This acquisition represents our commitment to advancing what’s possible in clinical evidence generation – building an end-to-end platform that integrates what patients say and what their bodies show. Patient-reported outcomes through eCOA capture what matters most – how patients feel and function in their daily lives. By bringing Ametris’ world-class technologies into Signant, we provide sponsors with complementary perspectives on patient functioning over time. This is particularly valuable in CNS and other complex therapeutic areas where sponsors need multiple lines of evidence to demonstrate meaningful benefit. Together, we’re giving sponsors the tools to build stronger, more comprehensive efficacy cases.”
Roger Smith, Chief Executive Officer, Signant Health
“Ametris has spent two decades developing regulatory-aligned wearable-derived measures of physical activity and function, captured objectively in patients’ natural environments. Joining Signant allows us to accelerate our vision of truly integrated multimodal evidence generation. Our combined expertise – Signant’s leadership in clinical outcome assessments (COA) and our strength in sensor-based measurement – creates something unique in the industry: a single partner committed to building purpose-designed integration. This benefits our customers through simplified vendor management today and seamless platform integration and converged workflows as our roadmap progresses.”
Jeremy Wyatt, Chief Executive Officer, Ametris
